MannKind 過去の業績
過去 基準チェック /36
MannKindは18.4%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで19.3%毎年増加している。売上は成長しており、年平均33.9%の割合である。
主要情報
18.4%
収益成長率
22.7%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | 33.9% |
| 株主資本利益率 | n/a |
| ネット・マージン | 8.1% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Oct 03MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17収支内訳
収支内訳
MannKind の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 267 | 22 | 91 | 44 |
| 30 Jun 24 | 248 | 12 | 91 | 41 |
| 31 Mar 24 | 225 | 8 | 93 | 36 |
| 31 Dec 23 | 199 | -12 | 94 | 31 |
| 30 Sep 23 | 177 | -31 | 96 | 29 |
| 30 Jun 23 | 158 | -47 | 95 | 23 |
| 31 Mar 23 | 128 | -71 | 95 | 22 |
| 31 Dec 22 | 100 | -87 | 91 | 20 |
| 30 Sep 22 | 76 | -98 | 92 | 16 |
| 30 Jun 22 | 66 | -88 | 87 | 16 |
| 31 Mar 22 | 70 | -94 | 81 | 13 |
| 31 Dec 21 | 75 | -81 | 77 | 12 |
| 30 Sep 21 | 81 | -79 | 72 | 10 |
| 30 Jun 21 | 75 | -86 | 68 | 8 |
| 31 Mar 21 | 66 | -61 | 62 | 7 |
| 31 Dec 20 | 65 | -57 | 59 | 6 |
| 30 Sep 20 | 63 | -45 | 58 | 7 |
| 30 Jun 20 | 62 | -44 | 60 | 7 |
| 31 Mar 20 | 62 | -46 | 63 | 7 |
| 31 Dec 19 | 63 | -52 | 75 | 7 |
| 30 Sep 19 | 63 | -47 | 77 | 6 |
| 30 Jun 19 | 53 | -61 | 80 | 6 |
| 31 Mar 19 | 42 | -71 | 85 | 8 |
| 31 Dec 18 | 28 | -87 | 80 | 9 |
| 30 Sep 18 | 16 | -110 | 85 | 11 |
| 30 Jun 18 | 13 | -119 | 83 | 13 |
| 31 Mar 18 | 12 | -131 | 80 | 14 |
| 31 Dec 17 | 11 | -117 | 75 | 14 |
| 30 Sep 17 | 20 | -31 | 67 | 12 |
| 30 Jun 17 | 180 | 129 | 62 | 12 |
| 31 Mar 17 | 178 | 134 | 55 | 18 |
| 31 Dec 16 | 175 | 126 | 47 | 15 |
| 30 Sep 16 | 162 | -205 | 38 | 20 |
| 30 Jun 16 | 0 | -364 | 35 | 21 |
| 31 Mar 16 | 0 | -363 | 35 | 19 |
| 31 Dec 15 | 0 | -368 | 41 | 30 |
| 30 Sep 15 | 0 | -128 | 44 | 39 |
| 30 Jun 15 | 0 | -133 | 53 | 54 |
| 31 Mar 15 | 0 | -177 | 75 | 83 |
| 31 Dec 14 | 0 | -198 | 79 | 100 |
| 30 Sep 14 | 0 | -216 | 84 | 112 |
| 30 Jun 14 | 0 | -230 | 83 | 120 |
| 31 Mar 14 | 0 | -203 | 65 | 110 |
質の高い収益: MNKDは 高品質の収益 を持っています。
利益率の向上: MNKD過去に利益を上げました。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: MNKD過去 5 年間で収益を上げており、収益は年間18.4%増加しています。
成長の加速: MNKDは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。
収益対業界: MNKD昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。
株主資本利益率
高いROE: MNKDの負債は資産を上回っているため、自己資本利益率を計算することは困難です。